Oncology

Merck files Keytruda for lung cancer, eyes first-line niche

Merck files Keytruda for lung cancer, eyes first-line niche

By

Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.

Five things for pharma marketers to know: Monday, April 20

Five things for pharma marketers to know: Monday, April 20

By

Teva eyes Mylan takeover; Keytruda shown to improve survival, shrink tumors in melanoma; ADHD abuse may follow grads into workforce.

Novartis leukemia drug ups progression-free survival

Late-stage results show Arzerra patients have a median progression-free survival rate almost double that of chemotherapy-only patients.

Five things for pharma marketers to know: Wednesday, April 15

Five things for pharma marketers to know: Wednesday, April 15

By

An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money

High cancer costs associated with better outcomes

High cancer costs associated with better outcomes

By

Researchers say countries that spend the most on cancer care have better outcomes, but the explanation behind improved mortality is not clear.

Rituxan may have rare-disease use

The cancer and immunology drug may help patients with a condition that affects two people in every one million.

Five things for pharma marketers to know: Friday, April 3

Five things for pharma marketers to know: Friday, April 3

By

Hedge fund activist challenges Shire patents; CMS issues documents on biosimilars; Astellas Pharma and the University of Texas MD Anderson Cancer Center partner on leukemia treatment

Five things for pharma marketers to know: Thursday, April 2

Five things for pharma marketers to know: Thursday, April 2

By

Celltrion expects its Remicade biosimilar to hit the US this year; Vivus cuts its sales force; BMJ accuses Novartis of interfering with clinical trials

Five things for pharma marketers to know: Wednesday, April 1

Five things for pharma marketers to know: Wednesday, April 1

By

Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused

Five things for pharma marketers to know: Thursday, March 26

Five things for pharma marketers to know: Thursday, March 26

By

Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk

Five things for pharma marketers to know: Friday, March 20

Five things for pharma marketers to know: Friday, March 20

By

A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik

ASCO wants to talk value when talking cancer

ASCO wants to talk value when talking cancer

By

An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.

US pharma market value projected to be $550 billion in five years

US pharma market value projected to be $550 billion in five years

By

Oncology and diabetes medications are expected to be major areas of growth.

Five things for pharma marketers to know: Tuesday, March 10

Five things for pharma marketers to know: Tuesday, March 10

By

HCV drugs and other specialty medications drove a 13% increase in last year's prescription spending, the CBO overestimated just how much healthcare reform would cost, and an FDA panel voted 17-0 in favor of Kythera's drug that can reduce double chins.

Imbruvica eases AbbVie's patent worries

Imbruvica eases AbbVie's patent worries

By

AbbVie's $21-billion bid to acquire Pharmacyclics may insulate the drugmaker from the impact of impending Humira biosimilars.

Five things for pharma marketers to know: Thursday, March 5

Five things for pharma marketers to know: Thursday, March 5

By

AbbVie nabs Pharmacyclics for $21 billion, Mallinckrodt makes a Pfizer-Hospira style acquisition, and the National Cancer Institute's director resigns

Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

By

The FDA granted the drug Priority Review status just last week.

Amgen results for Kyprolis could sideline Velcade

Amgen results for Kyprolis could sideline Velcade

By

Analysts say head-to-head study results could make Kyprolis the lead treatment.

Global cancer drug market to grow to $111 billion by 2020: report

Global cancer drug market to grow to $111 billion by 2020: report

By

The global cancer market is expected to reach $111 billion by 2020, according to new market research, with immunotherapies—particularly in lung cancer—expected to drive growth.

UK doctors lobby for off-label Avastin use

Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.

Study shows Lucentis at Eylea disadvantage

Study shows Lucentis at Eylea disadvantage

By

An NIH study shows possible limit to Lucentis's appeal.

Five things for pharma marketers to know: Friday, February 13

Five things for pharma marketers to know: Friday, February 13

By

FDA approves Eisai's thryoid cancer drug two months early, Gilead and Germany agree to a Sovaldi price cut, and Valeant looks set to make a bid for Salix.

Study shows impact of the "Angelina Jolie effect"

Study shows impact of the "Angelina Jolie effect"

By

AARP researchers found that the celebrity's decision to go public triggered a surge in genetic screening.

Five things for pharma marketers to know: Thursday, February 12

Five things for pharma marketers to know: Thursday, February 12

By

Hospira is planning a Lucentis biosimilar, Roche is expanding is cancer diagnostics portfolio, and cholesterol may not be as bad as originally thought (but smoking is worse than ever).

Survey shows cancer cause-effect awareness lacking

A survey showed patients are not really clear on what causes cancer.

Pfizer Ibrance is first approved CDK inhibitor

Pfizer Ibrance is first approved CDK inhibitor

By

The FDA approved the breast cancer drug Tuesday afternoon. Estimated peak sales: $3.8 billion.

Lilly expands Trulicity marketing push, lowers 2015 guidance

Lilly expands Trulicity marketing push, lowers 2015 guidance

By

The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.

Five things for pharma marketers to know: Friday, January 30

Five things for pharma marketers to know: Friday, January 30

By

Obama's precision medicine initiative looks set for bipartisan support, Valeant has offered $296 million to buy Dendreon and researchers say Roche's Tamiflu works.

J&J's Imbruvica snares fourth indication

J&J's Imbruvica snares fourth indication

By

The label will now include Waldenstrom's macroglubulinemia.

Amgen, Novartis, BMS map future

Amgen, Novartis, BMS map future

By

Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters